Although opicinumab did not demonstrate a statistically significant effect on remyelination in this study, the potential delay in CDMS onset and improvements in mfVEP latency suggest that further investigation into LINGO-1 inhibition as a therapeutic strategy for MS may be warranted [184]. This evidence concerns the gene LINGO1 and myeloid sarcoma.